Background
Cilostazol and isosorbide mononitrate (ISMN) have effects that may be beneficial in patients with cerebral small vessel disease and lacunar ischaemic stroke. We assessed their haemodynamic effects in the lacunar intervention-1 (LACI-1) trial.
Methods
Patients with lacunar ischaemic stroke were randomised to immediate ISMN, cilostazol, or their combination for 9 weeks. A fourth group received both drugs but with a delayed start. Peripheral blood pressure (BP) and heart rate (HR), and central haemodynamics 
Results
We recruited 57 patients; those allocated cilostazol alone were older but otherwise the groups were well-balanced at baseline. At week 8, BP did not differ between the treatment groups, whilst HR was significantly higher in those taking cilostazol vs. no cilostazol (MD 6.42, 95% CI 1.17-11.68, p=0.017). BI (subendocardial perfusion) was significantly lower in those randomised to cilostazol vs. no cilostazol and in those randomised to both drugs vs. either drug. There was a tendency towards reduced AI (arterial stiffness) adjusted for HR in those taking cilostazol vs. no cilostazol and ISMN vs. no ISMN.
Conclusions
In patients with lacunar ischaemic stroke, cilostazol increased HR (a recognised effect) which may account for the reduced BI; both agents may reduce arterial stiffness. Larger trials are warranted.
